フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million PR...
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 PR...
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of...
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 PR Newswire VICTORIA, BC...
Eupraxia Pharmaceuticals Strengthens Senior Management Team PR Newswire VICTORIA, BC, Oct. 2, 2024 VICTORIA...
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases PR Newswire VICTORIA...
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of...
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR...
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Aug. 7, 2024...
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility PR Newswire VICTORIA, BC, Aug...
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo PR Newswire VICTORIA, BC, July 8, 2024 VICTORIA...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders PR Newswire VICTORIA, BC, June 6, 2024...
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of...
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約